<SEC-DOCUMENT>0001564590-22-023488.txt : 20220617
<SEC-HEADER>0001564590-22-023488.hdr.sgml : 20220617
<ACCEPTANCE-DATETIME>20220617060157
ACCESSION NUMBER:		0001564590-22-023488
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220616
FILED AS OF DATE:		20220617
DATE AS OF CHANGE:		20220617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MESOBLAST LTD
		CENTRAL INDEX KEY:			0001345099
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37626
		FILM NUMBER:		221022332

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
		BUSINESS PHONE:		613 9639 6036

	MAIL ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>meso-6k_20220614.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
meso-6k_20220614.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91.55%;">
<tr>
<td style="width:468pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:double 3pt #000000;">
<p style="margin-top:5pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;;font-size:15pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:36pt;;">UNITED STATES <br />SECURITIES AND EXCHANGE COMMISSION</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:3pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:18pt;">Form&#160;6-K</font><font style="font-size:18pt;font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Foreign Private Issuer<br />Pursuant to Rule&#160;13a-16 or 15d-16 under the Securities Exchange Act of 1934<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the month of June 2022</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number 001-37626</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Exact name of Registrant as specified in its charter</font>)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Translation of Registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia<font style="font-weight:normal;"><br />(</font><font style="font-style:italic;font-weight:normal;">Jurisdiction of incorporation or organization)</font></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Silviu Itescu</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Executive Director</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Address of principal executive offices</font>)</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F:</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;20-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font> Form&#160;40-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font> No <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font> No <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="garf2phakigj000001.jpg" title="" alt="" style="width:0px;height:2px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 14, 2022, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement which is attached hereto as <font style="text-decoration:underline;">Exhibit 99.1</font>, and is incorporated herein by reference.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES<font style="font-weight:normal;"> </font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:120.28%;">
<tr>
<td valign="bottom"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.76%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:35.38%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.76%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:8.82%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:29.4pt;;text-indent:-29.4pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:29.4pt;;text-indent:-29.4pt;;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Mesoblast Limited</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Niva Sivakumar</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Niva Sivakumar</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Company Secretary</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: June 16, 2022</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO EXHIBITS</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:93.64%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:3.74%;white-space:nowrap;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:9pt;">
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Press release of Mesoblast Ltd, dated June 14, 2022.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>meso-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
meso-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmo1f5cke1e3000001.jpg" title="" alt="" style="width:242px;height:30px;"></p></td>
<td valign="top"  style="width:47.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmo1f5cke1e3000002.jpg" title="" alt="" style="width:277px;height:53px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk103115444"></a><a name="_Hlk57725371"></a>LITIGATION UPDATE </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">Melbourne, Australia; June 14 and New York, USA; June 13, 2022 <font style="font-weight:normal;">(ASX:MSB; Nasdaq:MESO): Further to our announcement of 19 May, 2022 regarding the proceeding served by the law firm William Roberts Lawyers,</font> <font style="font-weight:normal;">a second class action proceeding in the Federal Court of Australia canvassing similar allegations has been served on the Company by the law firm Phi Finney McDonald. Mesoblast will vigorously defend both proceedings.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously announced, in the U.S. the Company recently resolved a similar suit for $2 million, with no admission of liability, which was paid by the Company&#8217;s insurer other than the minimum excess as per the Company&#8217;s insurance policy. &#160;The court granted preliminary approval of the settlement on 8 April 2022 and has scheduled a final approval hearing for 15 August 2022. &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">About Mesoblast </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62221615"></a>Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company&#8217;s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast&#8217;s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see <font style="text-decoration:underline;">www.mesoblast.com</font>, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast&#8217;s preclinical and clinical studies, and Mesoblast&#8217;s research and development programs; Mesoblast&#8217;s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast&#8217;s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including BLA resubmission), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast&#8217;s product candidates, if approved; <br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:57.7pt;">
<td valign="top"  style="width:10.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<br /><font style="font-weight:normal;">ABN 68 109 431 870</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.mesoblast.com</font></p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Headquarters</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Australia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;"> </font><font style="font-size:7pt;font-weight:normal;">+61 3 9639 6036</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +61 3 9639 6030</font></p></td>
<td valign="top"  style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">United States Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505 Fifth Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2060</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2061</font></p></td>
<td valign="top"  style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Asia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Biopolis Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#01-22 Nucleos (South Tower)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SINGAPORE 138567</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +65 6570 0635</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +65 6570 0176</font></p></td>
<td valign="top"  style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  BGCOLOR="#1266AE" style="width:10.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmo1f5cke1e3000001.jpg" title="" alt="" style="width:242px;height:30px;"></p></td>
<td valign="top"  style="width:47.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmo1f5cke1e3000002.jpg" title="" alt="" style="width:277px;height:53px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast&#8217;s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast&#8217;s ability to enter into and maintain established strategic collaborations; Mesoblast&#8217;s ability to establish and maintain intellectual property on its product candidates and Mesoblast&#8217;s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast&#8217;s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast&#8217;s financial performance; developments relating to Mesoblast&#8217;s competitors and industry; and the pricing and reimbursement of Mesoblast&#8217;s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast&#8217;s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release authorized by the Chief Executive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;text-transform:none;font-variant: normal;">For more information, please contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:89.48%;">
<tr>
<td style="width:44.72%;"></td>
<td style="width:44.76%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;">Corporate Communications / Investors</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;">Media</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paul Hughes</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sumit Media</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T: +61 3 9639 6036</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Titmus</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">investors@mesoblast.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T: +61 419 388 161</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">grant@sumitmedia.com.au</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rubenstein</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tali Mackay</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">tmackay@rubenstein.com</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:57.7pt;">
<td valign="top"  style="width:10.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<br /><font style="font-weight:normal;">ABN 68 109 431 870</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.mesoblast.com</font></p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Headquarters</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Australia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;"> </font><font style="font-size:7pt;font-weight:normal;">+61 3 9639 6036</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +61 3 9639 6030</font></p></td>
<td valign="top"  style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">United States Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505 Fifth Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2060</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2061</font></p></td>
<td valign="top"  style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Asia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Biopolis Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#01-22 Nucleos (South Tower)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SINGAPORE 138567</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +65 6570 0635</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +65 6570 0176</font></p></td>
<td valign="top"  style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  BGCOLOR="#1266AE" style="width:10.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmo1f5cke1e3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmo1f5cke1e3000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O 7L# 2(  A$! Q$!_\0
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M;8HR/ NS.6 (..O6IO"7A>QU;1X-;UR(:CJ-XN]I+CY@J]% 7IT [5J?$/\
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LH.V< ]/>NXTS3X-)TRVL+8'R8(PBYZG'<^YZU;HISJRFK/\ R%"E&#NC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gmo1f5cke1e3000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmo1f5cke1e3000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 ;(# 2(  A$! Q$!_\0
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M2:?XET/5I?*T_5[&ZEQGRXIU9ORSFLN5[EW1J4444AGBWQTU"]LK_11:7=Q
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M -&2USWAU_$?B'15\(:%"_DO.]S=,K;58$*HWGLHV].^?85T/QW_ .1XLO\
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F=(BEWI9NY$>5C##('7GL<U[$!@8'2BBMJWV?0B'7U"BBBL2S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>garf2phakigj000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 garf2phakigj000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  )  ,# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
